$ATYR
aTyr Pharma Inc

2023 Q4 Form 10-Q Financial Statement

#000095017023062058 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $353.0K
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.204M $2.650M
YoY Change -6.48% -26.9%
% of Gross Profit
Research & Development $12.76M $10.32M
YoY Change -14.45% 4.58%
% of Gross Profit
Depreciation & Amortization $175.0K $180.0K
YoY Change 348.72% 267.35%
% of Gross Profit
Operating Expenses $15.96M $12.97M
YoY Change -12.96% -3.88%
Operating Profit -$12.62M
YoY Change -6.5%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.198M $1.273M
YoY Change 180.56% 415.38%
Pretax Income -$14.76M -$11.34M
YoY Change 96.21% -14.38%
Income Tax
% Of Pretax Income
Net Earnings -$14.76M -$11.30M
YoY Change 96.25% -14.39%
Net Earnings / Revenue -3201.13%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.25 -$0.20
COMMON SHARES
Basic Shares Outstanding 58.56M 57.05M
Diluted Shares Outstanding 57.89M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.17M $102.1M
YoY Change 48.41% 32.0%
Cash & Equivalents $22.54M $9.787M
Short-Term Investments $75.62M $92.34M
Other Short-Term Assets $2.390M $3.100M
YoY Change -18.98% -51.46%
Inventory
Prepaid Expenses $2.390M $3.080M
Receivables
Other Receivables $2.436M $2.087M
Total Short-Term Assets $103.0M $107.3M
YoY Change 27.35% 26.78%
LONG-TERM ASSETS
Property, Plant & Equipment $14.05M $5.644M
YoY Change 359.17% 342.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.615M $73.00K
YoY Change 1773.06% -56.8%
Total Long-Term Assets $17.66M $17.77M
YoY Change 18.41% 55.59%
TOTAL ASSETS
Total Short-Term Assets $103.0M $107.3M
Total Long-Term Assets $17.66M $17.77M
Total Assets $120.7M $125.1M
YoY Change 25.96% 30.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.529M $2.043M
YoY Change 13.62% -34.71%
Accrued Expenses $12.39M $9.605M
YoY Change 25.63% 32.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $497.0K $500.0K
YoY Change 88.26% 216.46%
Total Short-Term Liabilities $16.42M $12.88M
YoY Change 18.42% 14.88%
LONG-TERM LIABILITIES
Long-Term Debt $1.428M $1.400M
YoY Change 41.81% 126.54%
Other Long-Term Liabilities $12.34M $12.50M
YoY Change 28.09% 73.18%
Total Long-Term Liabilities $13.77M $13.90M
YoY Change 29.39% 77.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.42M $12.88M
Total Long-Term Liabilities $13.77M $13.90M
Total Liabilities $30.00M $26.70M
YoY Change 23.32% 41.49%
SHAREHOLDERS EQUITY
Retained Earnings -$468.0M -$453.3M
YoY Change 12.07% 10.53%
Common Stock $63.00K $59.00K
YoY Change 117.24% 103.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $90.66M $98.39M
YoY Change
Total Liabilities & Shareholders Equity $120.7M $125.1M
YoY Change 25.96% 30.21%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$14.76M -$11.30M
YoY Change 96.25% -14.39%
Depreciation, Depletion And Amortization $175.0K $180.0K
YoY Change 348.72% 267.35%
Cash From Operating Activities -$11.06M -$9.560M
YoY Change 6.68% -22.16%
INVESTING ACTIVITIES
Capital Expenditures $17.00K $560.0K
YoY Change -98.48% -231.46%
Acquisitions
YoY Change
Other Investing Activities $17.84M $4.940M
YoY Change 472.0% -76.56%
Cash From Investing Activities $17.82M $4.380M
YoY Change 791.35% -78.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.034M 2.690M
YoY Change 557.3% -10.72%
NET CHANGE
Cash From Operating Activities -11.06M -9.560M
Cash From Investing Activities 17.82M 4.380M
Cash From Financing Activities 6.034M 2.690M
Net Change In Cash 12.79M -2.490M
YoY Change -271.63% -121.88%
FREE CASH FLOW
Cash From Operating Activities -$11.06M -$9.560M
Capital Expenditures $17.00K $560.0K
Free Cash Flow -$11.08M -$10.12M
YoY Change -3.56% -14.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001339970
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20230930#LicenseAndCollaborationRevenuesMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://www.atyrpharma.com/20230930#LicenseAndCollaborationRevenuesMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37378
dei Entity Registrant Name
EntityRegistrantName
ATYR PHARMA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-3435077
dei Entity Address Address Line1
EntityAddressAddressLine1
10240 Sorrento Valley
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
731-8389
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
LIFE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
58560061
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9787000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9981000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
92344000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
56165000
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2087000
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
11775000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3080000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2950000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
107298000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
80871000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3451000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3165000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5644000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3059000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6812000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7250000
CY2023Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1791000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1248000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
73000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
193000
CY2023Q3 us-gaap Assets
Assets
125069000
CY2022Q4 us-gaap Assets
Assets
95786000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2043000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3106000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9605000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9862000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
630000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
459000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
264000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12881000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13862000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12548000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9633000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1437000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1007000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
85000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58560061
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58560061
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
29498488
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29498488
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
59000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
29000
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
551888000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
489502000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
98390000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
71464000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-187000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-294000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-433000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453263000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-417634000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-180000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98203000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71284000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
125069000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95786000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
353000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
353000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
353000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
353000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10319000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9867000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29538000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27898000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2649000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3625000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9775000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10556000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
12968000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
13492000
us-gaap Operating Expenses
OperatingExpenses
39313000
us-gaap Operating Expenses
OperatingExpenses
38454000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12615000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13492000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38960000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38454000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1273000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
247000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3324000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
634000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-11342000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
us-gaap Profit Loss
ProfitLoss
-35636000
us-gaap Profit Loss
ProfitLoss
-37820000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-2000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-1000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-7000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-3000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11340000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-13244000
us-gaap Net Income Loss
NetIncomeLoss
-35629000
us-gaap Net Income Loss
NetIncomeLoss
-37817000
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2023Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
2790000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.46
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.46
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.34
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57885393
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57885393
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28663047
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28663047
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51700864
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51700864
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28184698
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28184698
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-11342000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
us-gaap Profit Loss
ProfitLoss
-35636000
us-gaap Profit Loss
ProfitLoss
-37820000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
141000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
139000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-406000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-11303000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-13104000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-35497000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-38226000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-2000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-1000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-7000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-3000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11301000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13103000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35490000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38223000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
71284000
CY2023Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1489000
CY2023Q1 life Issuance Of Common Stock From Underwritten Follow On Offering Net Of Offering Costs
IssuanceOfCommonStockFromUnderwrittenFollowOnOfferingNetOfOfferingCosts
48073000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
619000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
185000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-11952000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109698000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65000
CY2023Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
8058000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
658000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-85000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-12342000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
106052000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
17124000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
664000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
39000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-11342000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98203000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
109126000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000
CY2022Q1 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
1480000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
417000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-496000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-12154000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
98374000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5000
CY2022Q2 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
34000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
517000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-51000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-12421000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
86458000
CY2022Q3 life Stock Issued During Period Value At The Market Offerings Net Of Offering Costs
StockIssuedDuringPeriodValueAtTheMarketOfferingsNetOfOfferingCosts
3037000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
615000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
141000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-13245000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
77006000
us-gaap Profit Loss
ProfitLoss
-35636000
us-gaap Profit Loss
ProfitLoss
-37820000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
417000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
193000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1941000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1549000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2278000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-565000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1917000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
805000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
13000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
95000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-9512000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-70000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
10000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1174000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-126000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
4878000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
2117000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-488000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22159000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31517000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4198000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
522000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
97312000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
63550000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
62713000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
15000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
179000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-37945000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
45246000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
65000
life Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
5000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
12337000
life Proceeds From Issuance Of Common Stock Through At Market Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughAtMarketOfferingNetOfOfferingCosts
4551000
life Proceeds From Issuance Of Common Stock Through Underwritten Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenPublicOfferingNetOfOfferingCosts
48073000
life Proceeds From Issuance Of Common Stock Through Underwritten Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockThroughUnderwrittenPublicOfferingNetOfOfferingCosts
24000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
279000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
60196000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4533000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
92000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
18262000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13146000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2336000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13238000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20598000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9787000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18359000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3451000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2239000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13238000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20598000
us-gaap Interest Paid Net
InterestPaidNet
133000
us-gaap Interest Paid Net
InterestPaidNet
0
life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
0
life Purchases Of Property And Equipment In Accounts Payable
PurchasesOfPropertyAndEquipmentInAccountsPayable
487000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1974000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
800000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-11300000
us-gaap Net Income Loss
NetIncomeLoss
-35600000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-453300000
CY2023Q3 life Cash And Cash Equivalents Restricted Cash And Available For Sale Investments
CashAndCashEquivalentsRestrictedCashAndAvailableForSaleInvestments
105600000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3500000
CY2023Q3 life Employee Retention Of Payroll Expenses
EmployeeRetentionOfPayrollExpenses
1200000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:5%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">unaudited condensed consolidated financial statements are prepared in accordance with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements requires us to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure for these items in our unaudited condensed consolidated financial statements and accompanying notes. The most significant estimates in our unaudited condensed consolidated financial statements relate to clinical trial</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">and </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">research and development expenses. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ materially from these estimates and assumptions.</span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4079484
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3114890
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
92587000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
244000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
92344000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
56548000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
383000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
56165000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
28
CY2023Q3 life Available For Sale Investments Number Of Positions
AvailableForSaleInvestmentsNumberOfPositions
29
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
1
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
2000000
CY2023Q3 life Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
200000
CY2022Q4 life Debt Securities Available For Sale Accrued Interest
DebtSecuritiesAvailableForSaleAccruedInterest
200000
CY2022Q2 us-gaap Area Of Land
AreaOfLand
23696
CY2023Q1 life Lessee Operating Lease Lease Commencement Date
LesseeOperatingLeaseLeaseCommencementDate
2023-03-20
CY2023Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P124M
us-gaap Lessee Operating Lease Lease Not Yet Commenced Option To Extend
LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
We have an option to extend the Lease Term for five years.
CY2022Q2 us-gaap Lessee Operating Lease Lease Not Yet Commenced Renewal Term1
LesseeOperatingLeaseLeaseNotYetCommencedRenewalTerm1
P5Y
CY2022Q2 life Base Rent Per Square Foot
BaseRentPerSquareFoot
5.75
CY2022Q2 life Annual Upward Adjustments On Base Rate Percentage
AnnualUpwardAdjustmentsOnBaseRatePercentage
0.03
CY2023Q3 us-gaap Tenant Improvements
TenantImprovements
5500000
us-gaap Payments For Proceeds From Tenant Allowance
PaymentsForProceedsFromTenantAllowance
5000000
CY2022Q2 life Additional Allowance For Tenant Improvements
AdditionalAllowanceForTenantImprovements
600000
CY2022Q2 life Base Rent Amortized Percentage
BaseRentAmortizedPercentage
0.08
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
700000
CY2023Q3 us-gaap Area Of Land
AreaOfLand
1500
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
476000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1915000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1975000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1923000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1942000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
11968000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6470000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
13729000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
774000
CY2023Q3 life Lessee Operating Lease Liability Tenant Improvement Allowance Not Yet Received
LesseeOperatingLeaseLiabilityTenantImprovementAllowanceNotYetReceived
407000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
12548000
CY2023Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
us-gaap Operating Lease Expense
OperatingLeaseExpense
1400000
us-gaap Operating Lease Expense
OperatingLeaseExpense
800000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y7M6D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.088
CY2023Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P48M
CY2023Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
148000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
595000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
595000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
638000
CY2023Q3 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
213000
CY2023Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
293000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
1896000
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
459000
CY2023Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1437000
CY2023Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y2M12D
CY2023Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.083
CY2022Q2 life Commission Rate Equal To Gross Proceeds1
CommissionRateEqualToGrossProceeds1
0.03
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8861728
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2956170
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.45
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1112885
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
96747
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
6.85
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3972308
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
664000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
615000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1941000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1549000

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0000950170-23-062058-index-headers.html Edgar Link pending
0000950170-23-062058-index.html Edgar Link pending
0000950170-23-062058.txt Edgar Link pending
0000950170-23-062058-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
life-20230930.htm Edgar Link pending
life-20230930.xsd Edgar Link pending
life-ex31_1.htm Edgar Link pending
life-ex31_2.htm Edgar Link pending
life-ex32_1.htm Edgar Link pending
life-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
life-20230930_cal.xml Edgar Link unprocessable
life-20230930_def.xml Edgar Link unprocessable
life-20230930_lab.xml Edgar Link unprocessable
life-20230930_pre.xml Edgar Link unprocessable
life-20230930_htm.xml Edgar Link completed
report.css Edgar Link pending
Show.js Edgar Link pending